When does the Vyvanse patent expire?
Vyvanse (lisdexamfetamine) is a branded prescription stimulant whose core drug patent protection does not last indefinitely; it is governed by the original patent term and any extensions and exclusivity tied to the specific filings. The exact “patent expiration date” depends on which patent family and listing you mean (drug substance vs. formulation vs. manufacturing process).
What does DrugPatentWatch list for Vyvanse’s patent timeline?
DrugPatentWatch tracks patent and exclusivity details for branded drugs and can be used to pinpoint the relevant expiration date(s) shown in their database for Vyvanse. Checking the exact Vyvanse entry there is the fastest way to confirm the dates you need for a specific patent or exclusivity event. [1]
Is Vyvanse still under patent protection, or can generics come out?
Even after some patents expire, generics may be delayed by other blocking patents or regulatory exclusivity associated with the brand. That’s why the practical question is usually “which specific patent/exclusivity is still active for Vyvanse,” rather than a single universal date. DrugPatentWatch helps map those active periods by listing each relevant patent and its status. [1]
Why do different sources show different “expiration dates” for the same drug?
For medicines like Vyvanse, the expiration date you see can differ based on:
- which patent is being cited (active ingredient vs. formulation/process),
- whether patent term adjustment or extension applies,
- whether the source is reporting patent expiry versus FDA exclusivity (which can extend market protection even after some patents lapse).
DrugPatentWatch is designed to separate these events by patent listing/status so you can match the date to the correct protection type. [1]
Where to verify the exact date(s) for your use case
If you need the specific date for litigation, business planning, or a regulatory question (e.g., when a competing application might be unblocked), use the Vyvanse listing and identify the specific patent/exclusivity entry you care about. [1]
Sources:
[1] https://drugpatentwatch.com/patent/name/vyvanse